Lean-mass loss is the recognized weakness of incretin monotherapy. Tracking the combination programs entering phase 2 that aim to fix it.
Muscle preservation during GLP-1 therapy: the myostatin combo pipeline
Replies
No replies yet. Be the first to add one.
The interesting question is whether preserving lean mass also preserves the metabolic-rate advantage through maintenance. The programs are powered for composition, not maintenance outcomes, unfortunately.